Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 (Patentes Nacionales, Patentes Europeas, Informes Tecnológicos de Patentes y Búsquedas Retrospectivas) está cerrado desde el pasado 19 de junio. Se informará más adelante sobre su reapertura.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
145
resultados
Última actualización
28/06/2025 [08:48:00]
Resultados 75 a 100 de 145
Resumen de: KR20250071871A
본 발명은 로즈마린산 유도체 및 이를 포함하는 알츠하이머 질환 예방, 개선 또는 치료용 조성물에 관한 것으로, 본 발명에서는 신규한 로즈마린산 유도체 14종을 합성하였으며, 이들 중 아밀로이드-베타(amyloid-β)와 타우 단백질 모두에 대해 플라그 형성을 억제하고 분해를 촉진하는 다중표적 효능을 가진 신물질 2종(RAD-5-9 및 RAD-5-21)을 선별하였다. 따라서, 본 발명의 신규한 로즈마린산 유도체는 알츠하이머 예방, 개선 또는 치료용 조성물로 유용하게 활용할 수 있다.
Resumen de: WO2025103285A1
Use of an innate phagocytosis-promoting polypeptide in preparing a drug for treating Alzheimer's disease.
Resumen de: WO2025102119A1
The present disclosure relates generally to the use of agents, such as oligonucleotides, to improve, increase, restore or retain the integrity of the blood brain barrier; and/or to reduce the deposition or accumulation of and/or promote the clearance of, amyloid-β. The disclosure also related to agents, such as oligonucleotides, that increase, promote or restore the level or amount of VE-cadherin in a cell, and are thus useful in the methods of the present disclosure. The present disclosure also relates to the use of such agents to treat diseases and conditions associated with damage to the blood brain barrier, including diseases and conditions associated with neuroinflammation and neurodegeneration, as well as diseases and conditions associated with amyloid-β deposition, including Alzheimer's disease (AD), Cerebral amyloid angiopathy (CAA), Lewy body dementia (LBD) and traumatic brain injury (TBI).
Resumen de: EP4556554A1
Provided are a Bifidobacterium longum subsp. infantis for alleviating Parkinson's disease and a use thereof, and the Bifidobacterium longum subsp. infantis for alleviating Parkinson's disease is named as Bifidobacterium longum subsp. infantis BI03 strain, with a deposit number of CGMCC No.24473 and deposit date of Mar. 7, 2022. The strain can significantly alleviate the symptoms of Parkinson's disease, specifically manifested in: alleviating Parkinson's disease-related dyskinesia and corticosterone elevation; weakening the neuroinflammation associated with Parkinson's disease; promoting glutathione and weakening brain oxidative stress damage.
Resumen de: EP4556014A1
Provided is a method for preventing, improving or treating Alzheimer's disease, dementia or brain function degeneration in a subject in need, including administering to the subject a composition comprising purified mushroom β-glucan, wherein the purified β-glucan is derived from mushroom mycelium or its fermentation product, wherein the purity of the purified mushroom β-glucan is 60% or above.
Resumen de: KR20250067974A
과제: 부작용이 적거나 없으며, 효과가 우수한 파킨슨병 예방 또는 치료용 약제를 제공하는 것. 해결수단: 본 발명자들은 PPA1 (Inorganic Pyrophosphatase 1) 단백질에 단백질 수송 도메인을 함께 융합시켜 세포 또는 조직으로의 침투를 가능하게 하여, PPA1 융합단백질이 MPP+와 MPTP로 유도한 도파민성 세포사멸과 파킨슨 동물 질환 모델에서 세포 보호효능을 발현하는지를 연구하였다. 그 결과, 세포 투과성 PPA1 융합단백질은 파킨슨병에서 효과적인 단백질 치료제로서의 가능성이 있음을 확인하였다.
Resumen de: US2025152747A1
Provided herein are expression cassettes for expressing a transgene in a cell, wherein the transgene encodes a GCase polypeptide. Also provided are methods to treat Gaucher Disease or GBA-PD. Further provided herein are vectors (e.g., rAAV vectors), viral particles, pharmaceutical compositions, and kits for expressing an GCase polypeptide in an individual in need thereof.
Resumen de: KR20250067698A
본 발명은 6-Aryl imidazo2,1-bthi/oxazole-2-carboxilic acid 유도체에 관한 것으로, 본 발명에 따른 화합물은 JNK3에 대해 특이적으로 작용할 수 있는, JNK3 억제제로 작용한다. 본 발명에 따른 화합물은 JNK1 및 JNK2에 대한 억제 활성에 비하여 JNK3에 대한 억제 활성이 상대적으로 높기 때문에 부작용의 위험성이 낮은 알츠하이머병 치료제로서 활용할 수 있다.
Resumen de: US2025152590A1
The invention provides a series of substituted aryl pyrimidine compounds and the use of these compounds as therapeuties to treat or prevent neurodegenerative disorders, including Parkinson's disease. Compounds of the invention are also able to treat the symptoms of such diseases and therefore represent a new treatment modality for ameliorating chronic and acute conditions. The compounds of the invention are capable of selectively potentiating the activity of the Nurr1:RXRα heterodimer, and are able to treat diseases or conditions associated with aberrant Nurr1:RXRα function. The invention further provides methods for treating neurodegenerative disorders by administration of Nurr1:RXRα activating agents.
Resumen de: US2025152659A1
A method for preventing or treating Parkinson's disease including administering a patient in need thereof a pharmaceutical composition including a polypeptide, the peptide having an amino acid sequence I or II: I: FPGSDRF (SEQ ID NO: 1)-Z; II: X-FPGSDRF (SEQ ID NO: 1)-Z; S represents phosphorylated serine; X and Z independently represents an amino acid or an amino acid sequence; X is selected from F, (R)9 (SEQ ID NO: 2), (R)9-F (SEQ ID NO: 3), 6-aminohexanoic acid, 6-aminohexanoic acid-F, 6-aminohexanoic acid-(R)9 (SEQ ID NO: 2), 6-aminohexanoic acid-(R)9-F (SEQ ID NO: 3); and Z is selected from (G)n-RGD or A-(G)n-RGD (SEQ ID NO: 4), where n is an integer greater than or equal to 0, in the range of 0-10.
Resumen de: US2025152541A1
The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
Resumen de: US2025152540A1
The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
Resumen de: WO2025098365A1
Disclosed are a levodopa nasal spray, a preparation method therefor, and use thereof. The levodopa nasal spray comprises levodopa or a pharmaceutically acceptable salt thereof, an absorption enhancer, a suspending agent, an antioxidant, a wetting agent, and an antimicrobial agent. The levodopa nasal spray enhances the stability of levodopa, increases olfactory region deposition of the drug, improves nasal-to-brain delivery efficiency, can effectively treat Parkinson's disease while reducing the occurrence of symptom fluctuations, and has suitable viscosity.
Resumen de: WO2025100469A1
According to the present invention, it is found that a snake venom metaloproteinase SVMP (snake venom metalloproteinase) from a snake belonging to the family Viperidae, the family Elapidae or the like decomposes Aβ and cuts the Aβ at an α-position to suppress the formation of Aβ fibrils. When a protein containing a metaloproteinase domain of SVMP is administered or a gene for the protein is introduced and is expressed in the brain, the formation of Aβ fibrils can be suppressed and consequently Alzheimer's disease can be treated.
Resumen de: US2025152539A1
The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
Resumen de: WO2025101004A1
The present invention relates to a 6-aryl imidazo(2,1-b)thi/oxazole-2-carboxilic acid derivative. The compound according to the present invention acts as a JNK3 inhibitor capable of acting specifically on JNK3. The compound according to the present invention has a relatively high inhibitory activity against JNK3 compared to inhibitory activities against JNK1 and JNK2, and thus can be used as a therapeutic agent for Alzheimer's disease with low risk of side effects.
Resumen de: US2025152542A1
The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.
Resumen de: US2025152543A1
The invention is a method for treating levodopa naïve patients with Parkinson's disease by orally administering a controlled release levodopa formulation twice a day to the levodopa naïve patient and the method provides an improvement of a patient's motor state as determined by patient's Parkinson's disease diary, provides a reduction of from about 10%-40% in the patient's tremor, dyskinesia, and/or mobility and/or provides a reduction in the patient's Movement Disorders Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores by at least 3 points.
Resumen de: WO2024011094A1
The present invention relates to the treatment of an ALS patient having disease onset of at least 24 months prior to initiation of treatment with fausdil. Fasudil is administered at a dose of 60-240 mg/day according to specific treatment regimens. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.
Resumen de: EP4552634A1
The present disclosure relates to a pharmaceutical composition useful for the prevention or treatment of diabetes, preservation of beta-cell function, hypertension, hyperlipidemia, obesity, non-alcoholic steatohepatitis, or neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, which includes a sustained-release microsphere containing semaglutide or a pharmaceutically acceptable salt thereof, a bioavailability enhancer and a biodegradable polymer, so that the pharmaceutical composition do not have a high initial burst of drug, contain a high content of drug relative to the particle size and have a high bioavailability, and thus, can minimize pain and inflammatory response of patient that may occur when administered to the human body.
Resumen de: EP4553069A1
Provided in the present invention are an α,β-unsaturated amide compound, and a preparation method therefor, and a pharmaceutical composition and the use thereof. Specifically, provided in the present invention is a compound as represented by formula I, wherein the definition of each group is as described in the description. The compound can be used as a compound for improving cerebral blood flow and is used for preparing a pharmaceutical composition for treating neurodegenerative diseases such as Alzheimer's disease and vascular dementia and strokes.
Resumen de: MX2025000057A
The present invention relates to the treatment of a ALS patient with oral fausdil at a dose of 180-240 mg/day, wherein the patient is treated beginning at least 24 months following disease onset. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.
Resumen de: KR20250064691A
과제: 부작용이 적거나 없으며, 효과가 우수한 파킨슨병 예방 또는 치료용 약제를 제공하는 것. 해결수단: 본 발명은 세포투과성 PGAM5 (포스포글리세레이트 뮤테이즈 5) 융합단백질을 포함하는 파킨슨병 치료용 약학 조성물에 관한 것으로서, 세포 내로 투과된 PGAM5 융합단백질이 MPP+로 유도한 도파민성 세포사멸과 파킨슨 동물 질환 모델에서 세포 보호효능을 발현하는지를 연구하였다. 그 결과, PGAM5 융합단백질은 파킨슨병에서 효과적인 단백질 치료제로서의 가능성이 있음을 확인하였다.
Resumen de: KR20250065159A
본 발명에서 파킨슨병을 효과적으로 치료할 수 있는 미토콘드리아 치료제를 제공한다. In vitro 실험 결과, 미토콘드리아 치료제(PN-101)는 신경독소에 의해 야기된 세포 사멸을 현저히 감소시켰다. 또한, PN-101은 LPS에 의해 유도된 항염증 사이토카인 발현을 완화시킴을 확인하였다. 뿐만 아니라, In vivo 실험 결과, PN-101은 DA 뉴런에서 신경 보호 효과를 나타내고, 미세아교세포 활성을 억제함으로써, MPTP 유발된 운동 이상을 개선할 수 있음을 확인하였다. 따라서, 미토콘드리아를 개체에 투여시 파킨슨병을 효과적으로 개선하거나 치료할 수 있음을 확인하였다.
Nº publicación: WO2025097160A1 08/05/2025
Solicitante:
THE MEDICAL COLLEGE OF WISCONSIN INC [US]
AIX MARSEILLE UNIV [FR]
THE MEDICAL COLLEGE OF WISCONSIN, INC,
AIX-MARSEILLE UNIVERSITE
Resumen de: WO2025097160A1
The present disclosure provides methods of enhancing levodopa therapeutic efficacy for the treatment of Parkinson's disease. The present methods can include administration of compounds having a triphenylphosphonium moiety. Advantageously, the present method can mitigate microbial metabolism of levodopa to dopamine in the gut, improve bioavailability of levodopa in brain, and increase dopamine levels in the brain.
BOPI
Sede Electrónica
